TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group

TriSalus Life Sciences (NASDAQ:TLSI) had its price objective lowered by Canaccord Genuity Group from $12.00 to $11.00 in a research note released on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

TLSI has been the topic of a number of other research reports. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective for the company. Northland Securities started coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price on the stock. Oppenheimer started coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $3.93 on Friday. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42. The business has a fifty day moving average price of $4.33 and a two-hundred day moving average price of $5.75. The stock has a market capitalization of $119.83 million, a PE ratio of -1.58 and a beta of 0.49.

Insiders Place Their Bets

In other news, CEO Mary T. Szela purchased 7,520 shares of the stock in a transaction on Thursday, September 12th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This trade represents a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Walleye Capital LLC bought a new position in TriSalus Life Sciences in the third quarter worth approximately $66,000. Vestcor Inc acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the 3rd quarter valued at $184,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the second quarter valued at $240,000. Finally, Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.